Cross-cultural adaptation, validity and reliability of the Turkish version of the patient determined disease steps scale in persons with multiple sclerosis

Kahraman, Turhan; Özdoğar, Asiye Tuba; Özakbaş, Serkan

doi:10.1080/09593985.2019.1633715

Cited by 16 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since SRDSS is a very new scale, its translations into other languages were not found in the literature. However, PDSS, which was developed as an alternative to EDSS, provides important data for our study because it is a questionnaire filled by the patient (Kahraman et al, 2021). The PDSS was developed to represent a patientreported outcome of the effect of MS on walking, while the SRDSS was developed to detect the EDSS interval with a patient-filled scale (Kaufmann et al, 2020;Schwartz et al, 1999).…”

Section: Discussionmentioning

confidence: 99%

“…Evaluations SRDSS described in this study was created to represent mobility-centered descriptions of predefined EDSS categories (Kaufmann et al, 2020). In addition, PDSS, which was developed as an alternative to EDSS, is used as a patient-reported outcome measure to assess disability in PwMS (Kahraman et al, 2021). Therefore, EDSS and PDSS were used to determine the reliability and validity of SRDSS.…”

Section: Translation and Cross-cultural Adaptationmentioning

confidence: 99%

“…The participant is asked to choose single items of the nine listed items (ranging from 0 to 8) that best describe their current walking ability status. These items are: "(0) normal"; "(1) mild disability"; "(2) moderate disability"; "(3) gait disability"; "(4) early cane"; "(5) late cane"; "(6) bilateral support"; "(7) wheelchair/scooter"; and "(8) bedridden" (Kahraman et al, 2021)…”

Section: Patient Determined Disease Steps Scalementioning

confidence: 99%

See 2 more Smart Citations

Validity and Reliability of the Turkish Version of the Self-Reported Disability Status Scale in Persons with Multiple Sclerosis

Bilek¹,

Demir²

2022

Balıkesır Health Sciences Journal

View full text Add to dashboard Cite

Objective:The aim of this study was designed to investigate the validity, reliability, and cultural adaptation of the Turkish version of the self-reported disability status scale (SRDSS). Materials and Methods: This study was designed as prospective, methodological, and cross-sectional. Turkish translation and cross-cultural adaptation of SRDSS was conducted. SRDSS scores were compared with Expanded Disability Status Scale and Patient Determined Disease Steps to test the concurrent validity. The validity and test-retest reliability of the Turkish SRDSS were investigated in 128 persons with MS. Results: A very strong correlation was found between SRDSS and Expanded Disability Status Scale (r=-0.920, p=0.000) and Patient Determined Disease Steps (r=0.857, p=0.000). The mean of the first test of SRDSS was 1.29±0.59, and the mean of the retest test was 1.30±0.61. A very high correlation was found between test and retest (p<0.001, r=0.967). Bland-Altman analysis showed that SRDSS was reproducible with upper and lower limits of agreement of 0.2929 and -0.3089, respectively (bias=-0.008; p=0.566). Cronbach's alpha coefficient was found to be 0.983 (excellent reliability). For inter-rater agreement, the ICC values in the individual test were 0.967 (954 CI; 0.954-0.977). Conclusion: This study showed that the Turkish version of SDRSS is a valid and reliable measurement tool. In cases where Expanded Disability Status Scale cannot be applied, the Turkish version of SRDSS can be used as an alternative assessment method.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Translation and Cross-cultural Adaptationmentioning

confidence: 99%

Section: Patient Determined Disease Steps Scalementioning

confidence: 99%

See 1 more Smart Citation

Validity and Reliability of the Turkish Version of the Self-Reported Disability Status Scale in Persons with Multiple Sclerosis

Bilek¹,

Demir²

2022

Balıkesır Health Sciences Journal

View full text Add to dashboard Cite

show abstract

“…Although a formal measure of disability was not utilized, the authors computed the patient determined disease steps (PDDS) score based on MS participants responses to questions related to their MS related symptoms and these symptoms impact on their life. Participants’ mean score on the PDDS was 3, indicating ”gait disability” ( Hohol et al, 1995 ; Kahraman et al, 2021 ). 42% of participants in the HA group were tested for COVID-19, and from them only 2 participants (1.6%) were positive.…”

Section: Methodsmentioning

confidence: 99%

Relationships between changes in daily occupations and health-related quality of life in persons with multiple sclerosis during the COVID-19 pandemic

Goverover

Chen

Botticello

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Background: The COVID-19 pandemic provided a unique opportunity to explore the impact of the mandated lockdown and social distancing policies on engagement in daily occupations for individuals with multiple sclerosis (MS) and able bodied (i.e. healthy) adults. The study also examined whether the changes in daily occupations were associated with health-related quality of life (HrQOL). Methods: Between the spring and early fall of 2020, 69 persons with MS and 95 healthy adults completed an online survey that included measurements of 26 activities of daily life. For each activity, participants reported whether they continued to perform the activity (with or without adjustments), whether they stopped, or started to perform the activity during the pandemic. Social support, HrQOL, and demographics, including financial distress were also obtained. Results: Participants with MS and healthy adults both reduced the number of activities performed during the pandemic. Healthy adults continued to do more activities with and without adjustments compared with participants with MS. In both groups, better HrQOL was associated with the number of activities participants continued to do with and without adjustments, and worse HrQOL with the number of activities they stopped doing. Conclusions: Fewer persons with MS engaged in everyday occupations than healthy adults following the COVID-19 pandemic. The ability to maintain occupational engagement and to participate in social and daily activities is important for maintaining high HrQOL in both groups. Thus, these results call for attention in treatment and self-management of MS symptomatology.

show abstract

“…No additional decrease in utility was applied if the subject was at the SPMS stage. The utilities determined in the study by Orme et al 24 were not chosen since the measurement of disability was conducted using the Adapted Patient Determined Disease Steps scale (APDDS), which differs from the EDSS in its scores (6.5 to10) 25 .…”

Section: Effects and Utilitiesmentioning

confidence: 99%

Cost-utility analysis comparing ocrelizumab vs rituximab in the treatment of relapsing-remitting multiple sclerosis: The Colombian perspective

Navarro

Betancur

Porras-Ramírez

2022

Preprint

View full text Add to dashboard Cite

Introduction: Since 2017, the ocrelizumab is available to treat patients with relapsing-remitting multiple sclerosis (RRMS), together with rituximab, they have a similar effectiveness but different costs. In this context, the added value provided by cost-effectiveness estimators for decision-making and drug prescription can be considered. Objective: to determine the cost-utility of ocrelizumab versus rituximab in patients with RRMS, from the perspective of the Colombian health system. Methodology: cost-utility study based on a Markov model, with a 50-year horizon and payer perspective. The currency was the US Dollar (USD) for the year 2019, with a threshold of $5,180 USD defined for Colombian health system. The model used annual cycles according to the health status determined by the disability scale. Direct costs were considered, and the incremental cost-effectiveness ratio (ICER) per 1 quality-adjusted life year (QALY) gained was used as the outcome measure. A discount rate of 5% was applied for costs and outcomes. Multiple one-way deterministic sensitivity analyzes and 10,000 modeling through Monte Carlo simulation were performed. Results: for the treatment of patients with RRMS, ocrelizumab versus rituximab had an ICER of $73,652 USD for each QALY gained. After 50 years, 1 subject treated with ocrelizumab earns 4.8 QALYs more than 1 subject treated with rituximab, but at a higher cost of $521,759 USD vs $168,752 USD, respectively. Ocrelizumab becomes a cost-effective therapy when its price is discounted >86%, or there is a high willingness to pay. Conclusions: Ocrelizumab was not a cost-effective drug compared with rituximab to treat patients with RRMS in Colombia.

show abstract

Cross-cultural adaptation, validity and reliability of the Turkish version of the patient determined disease steps scale in persons with multiple sclerosis

Cited by 16 publications

References 25 publications

Validity and Reliability of the Turkish Version of the Self-Reported Disability Status Scale in Persons with Multiple Sclerosis

Validity and Reliability of the Turkish Version of the Self-Reported Disability Status Scale in Persons with Multiple Sclerosis

Relationships between changes in daily occupations and health-related quality of life in persons with multiple sclerosis during the COVID-19 pandemic

Cost-utility analysis comparing ocrelizumab vs rituximab in the treatment of relapsing-remitting multiple sclerosis: The Colombian perspective

Contact Info

Product

Resources

About